Dream ePRO is an electronic patient reported outcome (ePRO) system designed by Landmark Research, which is offered as a software as a service (SaaS) for its clients to collect data via ePRO devices to enable the clients to manage the subject’s questionnaires and diaries in their clinical studies.

Dream ePRO is a web-based platform that allows the users to perform the following functions: ​
EPRO Data Collection​

Dream ePRO enables the users to collect the data from the subjects, using various ePRO devices, such as smartphones, tablets, computers, and wearable devices. Dream ePRO supports various types of data, such as symptoms, quality of life, satisfaction, adherence, and preferences. Dream ePRO also supports various modes of data collection, such as self-administered, interviewer-administered, and mixed-mode.

EPRO Data Analysis And Reporting

Dream ePRO enables the users to analyze and report the data collected from the subjects, using various methods and techniques, such as descriptive statistics, inferential statistics, psychometric analysis, and patient-reported outcome (PRO) measures. Dream ePRO also offers data integration, data visualization, and data analytics services, to support decision making and knowledge generation. Dream ePRO ensures the validity, reliability, and usability of the ePRO data, as well as compliance with the data analysis and reporting guidelines and best practices, such as the Consolidated Standards of Reporting Trials (CONSORT) statement for ePRO, the International Society for Quality of Life Research (ISOQOL) standards for ePRO, and the Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID).

EPRO Data Management

Dream ePRO enables the users to manage the data collected from the subjects, using various tools and features, such as data validation, data cleaning, data encryption, data backup, and data export. Dream ePRO ensures the quality, integrity, and security of the ePRO data, as well as compliance with the data standards and regulations, such as the Food and Drug Administration (FDA) guidance on ePRO, the European Medicines Agency (EMA) guideline on ePRO, and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) best practices for ePRO.